Twist Bioscience (NASDAQ:TWST) reported first-quarter fiscal 2026 results Monday that beat revenue expectations and showed significant margin improvement, as the company stays on track to reach its profitability goals by the end of the year.
The South San Francisco-based synthetic DNA pioneer posted revenue of $103.7 million, a 17% increase year-over-year, driven by record demand for its Next-Generation Sequencing (NGS) and synthetic biology portfolios.
While the company reported a net loss of $30.5 million, or $0.50 per share, its operational health continued to trend upward.
Gross margins rose to 52%, reflecting the benefits of increased manufacturing scale at its "Factory of the Future" in Oregon.
The quarterly loss matched analyst consensus estimates, while revenue exceeded the high end of the company's previous guidance of $101 million.
Management expressed high confidence in the 2026 trajectory, raising its full-year revenue outlook to a range of $435 million to $440 million.
A primary catalyst remains the company’s push into the minimal residual disease (MRD) market and AI-driven drug discovery projects, which have accelerated order volumes.
CEO Emily Leproust reaffirmed that Twist remains on a "clear path" to achieve adjusted EBITDA breakeven by the fourth fiscal quarter of 2026.